Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AVXLNASDAQ:HLVXNASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$20.45+2.4%$20.28$8.42▼$25.67$4.86B0.573.71 million shs4.58 million shsAVXLAnavex Life Sciences$8.55+3.6%$8.93$3.51▼$14.44$704.32M0.821.22 million shs735,040 shsHLVXHilleVax$1.89-0.5%$1.71$1.34▼$16.31$94.77M0.78446,530 shs98,248 shsSANASana Biotechnology$2.00+9.9%$1.92$1.26▼$9.49$450.95M1.753.32 million shs8.69 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+2.30%-13.75%+5.41%+28.78%+132.12%AVXLAnavex Life Sciences+3.64%-4.04%-3.50%+3.14%+124.41%HLVXHilleVax-0.53%-1.56%+13.17%+8.62%-86.34%SANASana Biotechnology+10.50%+6.95%+13.64%-27.54%-73.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.1351 of 5 stars2.61.00.00.03.21.71.9AVXLAnavex Life Sciences3.8256 of 5 stars3.71.00.04.72.70.80.6HLVXHilleVax2.7769 of 5 stars3.02.00.00.03.03.31.3SANASana Biotechnology1.9017 of 5 stars3.40.00.00.01.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2518.58% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00414.62% UpsideHLVXHilleVax 2.00Hold$3.0058.73% UpsideSANASana Biotechnology 2.86Moderate Buy$10.80440.00% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, HLVX, SANA, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/18/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/18/2025SANASana BiotechnologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.003/14/2025SANASana BiotechnologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.003/4/2025ADMAADMA BiologicsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.002/18/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.58$0.07 per share311.70$0.60 per share34.08AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8573.0429.64N/A17.80%53.20%26.07%N/AAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%5/13/2025 (Estimated)HLVXHilleVax-$123.57M-$2.15N/AN/AN/AN/A-67.27%-51.99%N/ASANASana Biotechnology-$283.26M-$0.88N/AN/AN/AN/A-84.22%-44.97%5/14/2025 (Estimated)Latest ADMA, HLVX, SANA, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16N/AN/AN/AN/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/A3/17/2025Q4 2024SANASana Biotechnology-$0.25-$0.23+$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26AVXLAnavex Life SciencesN/A9.459.45HLVXHilleVaxN/A14.2514.25SANASana BiotechnologyN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AVXLAnavex Life Sciences31.55%HLVXHilleVax86.42%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%AVXLAnavex Life Sciences11.40%HLVXHilleVax71.10%SANASana Biotechnology30.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530237.62 million227.64 millionOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableHLVXHilleVax2050.14 million14.39 millionNot OptionableSANASana Biotechnology380225.48 million153.83 millionOptionableADMA, HLVX, SANA, and AVXL HeadlinesRecent News About These CompaniesSana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Expectations By $0.02 EPSMay 12 at 11:36 PM | marketbeat.comSana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANAMay 12 at 8:15 PM | accessnewswire.comSana Biotechnology to Present at the BofA Securities 2025 Healthcare ConferenceMay 12 at 4:05 PM | globenewswire.comSana Biotechnology, Inc. Class Action: The Gross Law Firm Reminds Sana Biotechnology, Inc. ...May 12 at 2:29 PM | gurufocus.comSANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud LawsuitMay 12 at 2:29 PM | gurufocus.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & KorsinskyMay 12 at 2:00 PM | accessnewswire.comSANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud LawsuitMay 12 at 1:59 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANAMay 12 at 1:39 PM | prnewswire.comSana Biotechnology, Inc. Class Action: The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANAMay 12 at 1:01 PM | globenewswire.comSANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMay 12 at 11:15 AM | accessnewswire.comROSEN, A LEADING NATIONAL FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANAMay 12 at 11:00 AM | accessnewswire.comSANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. ...May 12 at 10:15 AM | gurufocus.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & KorsinskyMay 12 at 10:15 AM | accessnewswire.comSANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 12 at 9:50 AM | prnewswire.comSana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANAMay 12 at 7:25 AM | accessnewswire.comSANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!May 12 at 7:00 AM | accessnewswire.comSana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact The ...May 12 at 6:05 AM | gurufocus.comSana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANAMay 12 at 5:45 AM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANAMay 11 at 9:00 PM | accessnewswire.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & KorsinskyMay 11 at 4:20 PM | accessnewswire.comContact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)May 11 at 9:47 AM | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s Lead3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketADMA, HLVX, SANA, and AVXL Company DescriptionsADMA Biologics NASDAQ:ADMA$20.45 +0.47 (+2.35%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$20.50 +0.05 (+0.27%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Anavex Life Sciences NASDAQ:AVXL$8.55 +0.30 (+3.64%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$8.55 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.HilleVax NASDAQ:HLVX$1.89 -0.01 (-0.53%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.85 -0.04 (-2.06%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Sana Biotechnology NASDAQ:SANA$2.00 +0.18 (+9.89%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$2.09 +0.09 (+4.50%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
